Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Serum Bio Technology CoSHSE:688163 -3.80%73 Return-on-Tangible-Asset is 12.23% as of Jun. 2026, which is 1% above its 10-year median of 12.06. GuruFocus rates SHSE:688163 with a GF Score™ of 73/100 and a GF Value™ of ¥21.35 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Shanghai Serum Bio Technology Co ranks better than 86.18% on this metric.
The historical rank and industry rank for Shanghai Serum Bio Technology Co's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:688163'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.45 Med: 12.06 Max: 40.59
Current: 4.79
During the past 13 years, Shanghai Serum Bio Technology Co's highest Return-on-Tangible-Asset was 40.59%. The lowest was 3.45%. And the median was 12.06%.
SHSE:688163's Return-on-Tangible-Asset is ranked better than 86.18% of 1411
companies
in the Biotechnology industry
Industry Median: -35.4
vs SHSE:688163: 4.79
Shanghai Serum Bio Technology Co (SHSE:688163) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Shanghai Serum Bio Technology Co Return-on-Tangible-Asset Related Terms
Shanghai Serum Bio Technology Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Serum Bio Technology Co Return-on-Tangible-Asset Chart
SHSE:688163 vs VRTX, REGN, MRNA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Shanghai Serum Bio Technology Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Serum Bio Technology Co Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Serum Bio Technology Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Shanghai Serum Bio Technology Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 12.23% mean?
Shanghai Serum Bio Technology Co (SHSE:688163) has a Return-on-Tangible-Asset of 12.23% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shanghai Serum Bio Technology Co and its competitors. This is near median its historical median of 12.06. Over the past decade, Shanghai Serum Bio Technology Co's Return-on-Tangible-Asset has ranged from 3.45 to 40.59. According to the industry distribution chart, Shanghai Serum Bio Technology Co ranks #195 out of 1411 companies in the Biotechnology industry, placing it in the top 13.8%.
Is Shanghai Serum Bio Technology Co's Return-on-Tangible-Asset too high?
Shanghai Serum Bio Technology Co's current Return-on-Tangible-Asset of 12.23% is near median its 10-year median of 12.06. Over the past 10 years, this metric has ranged from a low of 3.45 to a high of 40.59. Based on the distribution chart, Shanghai Serum Bio Technology Co ranks #195 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Serum Bio Technology Co has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Serum Bio Technology Co's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Serum Bio Technology Co ranks #195 out of 1411 companies for Return-on-Tangible-Asset. This places Shanghai Serum Bio Technology Co in the top 14% of its industry — outperforming the majority of peers. Historically, Shanghai Serum Bio Technology Co's own Return-on-Tangible-Asset has ranged from 3.45 to 40.59 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shanghai Serum Bio Technology Co and its competitors. Shanghai Serum Bio Technology Co's current Return-on-Tangible-Asset is 12.23%, which is near median its own 10-year median of 12.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Serum Bio Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Serum Bio Technology Co (SHSE:688163) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥21.35, compared to a current price of ¥33.90 — trading 58.8% above its estimated fair value. The current Return-on-Tangible-Asset is 12.23%, which is near median its 10-year median of 12.06. Shanghai Serum Bio Technology Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Shanghai Serum Bio Technology Co (SHSE:688163), the current Return-on-Tangible-Asset is 12.23% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Serum Bio Technology Co (SHSE:688163) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Serum Bio Technology Co stock appears to be overvalued.
The current stock price of ¥33.90 is trading 58.8% above its estimated GF Value™ of ¥21.35.
GuruFocus considers Shanghai Serum Bio Technology Co to be Significantly Overvalued.
Key valuation signals for SHSE:688163:
Return-on-Tangible-Asset: 12.23% (near median its 10-year median of 12.06)
GF Value™: ¥21.35 vs. price of ¥33.90 (58.8% above fair value)
No single metric tells the full story. See the SHSE:688163 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Serum Bio Technology Co Ltd is engaged in the research, development, production and sales of preventive and therapeutic drugs in the field of biotoxins and biosafety.
73GF Score
Get the complete analysis for SHSE:688163
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688163 has been successfully added to your 
